Hawaii Island Natives to Star During the 75th Hula Bowl – Big Island Now

Hawaii fashion designer, Manaola Yap, will star during the 2021 Hula Bowl halftime show.

This year marks the games 75th edition which will kickoff at Aloha Stadium, showcasing 100 of the nations best college football seniors. Even though were not able to have a live halftime show this year, my wife saw an opportunity and it made so much sense to have Manaola share his story about what hula means to him during the Hula Bowl, said Rich Miano, Executive Director of the Hula Bowl. We couldnt be more excited to share what has been created.

As a native Hawaiian hula practitioner, Yap narrated a poetic monologue on what hula means to him while Hula Halau Manaola performed A Koaekea I Pueohulunui during which Yap is shown chanting with his mother, Kumu Hula Nani Lim Yap, by his side. Everyone in hula has their own perspective on what hula is so I wanted to respect that and share what hula is to me through what I was taught while growing up, said Yap. Around the world, the view of what Hula is, has been different. This halftime show is about taking back that cultural narrative and helping the audience to experience the true meaning, essence, and power that hula is.

The show segment is directed by Hilo native, Tracey Niimi who assembled a team of local video producers to film the at the Kahilu Theater in Kamuela. I think we all felt that weight of responsibility to our community to create a piece that not only properly represented the Hawaiian culture, but was a piece that our entire state would be proud of sharing with the rest of our country, said Niimi.

The 75th Hula Bowl kicks off Sunday, Jan. 31 at 4:30 p.m. No spectators will be in attendance but the game will air on CBS Sports Network and streamed on the CVS Sports App.

Continue reading here:

Hawaii Island Natives to Star During the 75th Hula Bowl - Big Island Now

Safety projects coming to US Highway 20 near Island Park – Rexburg Standard Journal

The Idaho Transportation Department announced it will initiate numerous safety improvements this year to the U.S. Highway 20 corridor through Island Park.

The projects include installing flashing lights on signs to alert drivers to approaching speed limit reductions, and installing dynamic Your Speed signs to inform those traveling southbound of their speeds, according to a department press release. A similar sign for northbound traffic already exists.

Megan Stark, transportation department public information officer, said the estimated cost of the safety projects is $1.62 million in an email to the Standard Journal.

The current condition of US-20 from Ashton to the Montana state line is in need of repairs and reconstruction, Stark said. This section of the roadway was originally built in the 1950s and 1960s and has reached the end of its design life.

Highway 20 is a well-travelled highway that connects to Yellowstone National Park, generating high volumes of traffic, Stark said. The transportation department also expects to see increased traffic in the future and has plans for expansion projects in that area.

The department will also cut back trees within the highway right of way in the corridor by the end of 2021. According to a transportation department press release, this will improve the line of sight for drivers and remove hiding places for wildlife approaching the road. Trees that could fall on the highway will be eliminated and sunlight will have better access on the road to melt icy spots.

In order to provide a safer corridor for the traveling public, ITD plans to make the appropriate short-term safety improvements to help improve the drivers line of sight, eliminate potential safety hazards and encourage drivers to drive safely, Stark said.

For fiscal year 2023, the department plans to add a signal light at the intersection of Highway 20 and state Highway 47.

View original post here:

Safety projects coming to US Highway 20 near Island Park - Rexburg Standard Journal

Fourteen Years and a Demolition Later, Greg Norman Lists Jupiter Island Home for $59.9 Million – The Wall Street Journal

Over a period of 14 years, golf legend Greg Norman has listed his Jupiter Island, Fla., home, reduced the price of his home, demolished his home and then replaced it with a large family compound filled with every bell and whistle he could think of.

Now he and his wife, Kiki Norman, have decided to sell and are listing the customized compound for $59.9 million.

Named Tranquility, the 10-bedroom estate is over 8 acres and has nearly 32,000 square feet of living space, including the main house, a carriage house, a pool house, a guesthouse and a boat house, according to the listing.

The home, completed last summer, has sprawling entertainment spaces, a bar, a trophy room and gallery, a large family room, an outdoor terrace, two offices, a luggage room and even a room for accessories like handbags, scarves and costume jewelry. There is also a more than 5,000-square-foot basement entertainment suite with a game room, a movie theater and two 1,900-bottle wine cellars.

Were on an island with hundreds of coconut trees, so it was very natural to build a coastal tropical beach house, said Ms. Norman, 52. My goal was to make the house feel like we were on permanent vacation.

Visit link:

Fourteen Years and a Demolition Later, Greg Norman Lists Jupiter Island Home for $59.9 Million - The Wall Street Journal

‘Greys Anatomy’ Star Katherine Heigl Weighs in on Izzies Return in Season 17 – GoodHousekeeping.com

Grey's Anatomy set major expectations for season 17 when the show brought back Derek Shepherd (Patrick Dempsey) for a dream scene in the premiere. Shocking fans even more, another blast from the past, George O' Malley (T.R. Knight), returned a few episodes later. All of this is leading fans to wonder what other iconic characters the ABC medical drama is going to invite back. Will Katherine Heigl's character, Izzie Stevens, be next?

Right now, the answer appears to be one giant question mark, according to what Katherine told E! News's Daily Pop. "You know, I just I don't know, but I would never say never," Katherine explained.

While it might not be the definite "yes" some fans are hoping for, Katherine, who is front and center in the new Netflix series Firefly Lane, didn't give a firm "no," either. If you ask us, it's a bit more promising answer than the response she gave Entertainment Tonight back in 2019.

"I almost feel like that would just be distracting, again, to sort of what theyve done with that show in the seven years since I left and what thats become and what it is to the fans now," she at the time. "I almost feel like it would be like, Yeah we already let that go, why are you here?'"

But then again, Katherine said this before Justin Chambers exited the show last March and his character, Alex Karev, left his wife, Jo (Camilla Luddington), to be with Izzie. So who knows what may unfold in the future.

As fans can remember, Katherine walked away from Grey's in 2010 following the actress's controversial decision to withdraw her name from Emmy consideration in 2008. At the time, Katherine said in a statement per The New York Times that she based her decision on feeling like she wasn't "given the material this season to warrant an Emmy nomination."

Not surprisingly, this didn't sit well with show creator Shonda Rhimes, who later told Oprah Winfrey in 2012 that despite feeling "stung" by the comments, she was also "not surprised."

On The Howard Stern Show in 2016, Katherine claimed she left the show partly because she wanted to start a family (she now has three kids with her husband, Josh Kelley) and because she felt herself "floundering." She also revealed that she had apologized to Shonda behind closed doors about her Emmy comments.

"I was really embarrassed." she said. "I went in to [showrunner] Shonda [Rhimes] and said, I was so sorry, that wasnt cool. I should not have said that.' I shouldnt have said anything publicly, but at the time I didnt think anybody would notice."

So there you have it. Fans will have to keep tuning in when Grey's returns on March 11 to see what Shonda has in store for the Grey-Sloan crew.

This content is imported from {embed-name}. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Excerpt from:
'Greys Anatomy' Star Katherine Heigl Weighs in on Izzies Return in Season 17 - GoodHousekeeping.com

The Anatomy of an African Wild Dog Hunt – PBS

The Anatomy of an African Wild Dog Hunt

Published: January 26, 2021

Narrator: In an African wilderness like Mozambique's Gorongosa National Park, each animal faces a fundamental taskday in, day outfinding something to eat.

Herbivores have an additional challenge: they must also avoid being eaten.

As for carnivores, to survive, they must kill. And to kill, they must hunt.

Paola Bouley: There's some dance that happens between those two groups of species. One doesn't want to be eaten, the other needs to eat. So, they each fulfill a unique niche in the ecology of the system.

Narrator: Two top carnivore species roam the forests and floodplains of Gorongosa: African wild dogs and lions. Each has their own particular style of hunting, and their own unique effect on the prey species around them.

Bouley: A lion is an ambush predator and our lions in Gorongosa tend to hang out in the tall grass and they almost literally wait for something to walk into their mouths. Theyre not out running on the flood plains chasing down prey. They dont have to spend that energy. Theres a stray waterbuck or a warthog thats just walking through the grass and all of a sudden, a lion is there. And it takes a split second for a lion to take it down.

Narrator: Prey are so plentiful in Gorongosa, lion rarely roam from their favorite grasslands, limiting their impact on the ecosystem.

Wide-ranging wild dogs provide an essential contrast.

Bouley: Compared to an ambush predator like a lion, a wild dog is a coursing predator. And that means that it chases down its prey. Its not sitting, lying in wait for something to walk up to its area. Its going to chase down what it wants to consume.

Narrator: Weighing less than eighty pounds, African wild dogs are built for speed and endurance. Their long, thin legs can carry them over a mile during a hunt and propel them at speeds approaching 40 miles an hour.

Bouley: Now, a lion is going to think twice about running after something, especially if they can just pick it out of the grass. But dogs are not stealthy in that sense. Theyre gregarious. Theyre playing together. Theyre noisy. Animals see them coming from far. Theyre not stealthy at all. So, they have to rely on the chasing.

Chasing, clearing, very different strategy to a lion.

Narrator: And there's much more to that strategy than simply out-running prey. The pack's meals emerge from an extraordinary routine.

Bouley: A typical day for the dogs right now is they tend to rest during the heat of the day but in the early mornings and late afternoons they begin to play, socialize more together and they hunt.

Antnio "Tonecas" Paulo: (Translated from Portuguese) About thirty minutes before the hunt, they start playing, and you can see at that stage that they start to lower their heads and prick up their ears a bit and they make a calling sound between them.

Bouley: So, we're looking at some of the best wild dog habit here. It's a wide-open expanse, really flat, hard substrateand they'll course through here.

They start moving across the landscape and then fractions of the pack break off and begin to select prey. Those dogs out in front who want to start hunting are out there already sussing everyone out.

Here we go.

Here in Gorongosa, we have palm thickets, and termite mounds and little patches of forest. Animals like a bushbuck or an oribi would be hunkered in the shade and what we have is a pack of dogs and a wave of teeth that are just sweeping through the landscape, sifting animals out of their refuges, and looking for that one weak moment.

Narrator: Once a victim is flushed out, the wild dogs kick into high gear.

Paulo: (Translated from Portuguese) They chase their prey at a very high speed. When this wave arrives, the prey has little chance to survive the attack.

Bouley: The beauty of a pack is that they function as a whole. Everybody needs to do well together. The sum is greater than the parts with a wild dog pack.

There's no fighting at kills. There's no outward aggression like you'll see with the lion. Everybody gets to eat, nothing is wasted. So, vultures will hang around, but there's very little scraps to be taken. They consume everything.

So, theyre having an impact on how animals are distributing themselves because herbivores understand: thats a predator. They are fulfilling a unique role as a coursing predator in this system. And thats a good thing.

PRODUCER / WRITER

David Murdock

EXECUTIVE PRODUCERS

Jared Lipworth

Sean B. Carroll

EDITOR

Emmanuel Mairesse

NARRATOR

Rodd Houston

DIRECTORS OF PHOTOGRAPHY

Erin Harvey

BRETT KUXHAUSEN

Sound Recordist

Sebastian Dunn

ORIGINAL MUSIC BY

Ivan Mairesse

HEAD OF PRODUCTION & DISTRIBUTION

Anne Tarrant

SUPERVISING PRODUCER

Heather Forbes

DIRECTOR OF OPERATIONS

Lori Beane

COORDINATING PRODUCER

Frank Verock

PRODUCTION MANAGER

Betsy Fielding

ASSOCIATE PRODUCER

Brenda Billoch

POST PRODUCTION SUPERVISOR

Indy Mitra

ASSISTANT EDITOR

Kelsey Johnson

RESEARCHER

Natalia Borrego

SCIENCE EDITOR

Aileen O'Hearn

POST PRODUCTION SERVICES

Henninger Media Services

STOCK FOOTAGE AND ARCHIVE

Gorongosa Media

HHMI Tangled Bank Studios is an initiative of and funded by the HHMI Department of Science Education. Its objective is to advance HHMI's mission of fostering understanding of science.

2020 Tangled Bank Studios, LLC

All Rights Reserved

View original post here:
The Anatomy of an African Wild Dog Hunt - PBS

Katherine Heigl struggled with ‘public shaming’ after ‘Grey’s Anatomy’ Emmy drama – Yahoo News

Katherine Heigl has opened up on being labelled difficult.

Actress Katherine Heigl has opened up on her struggle with being publicly shamed and bullied over the fallout from her criticism of hit TV show Greys Anatomy.

Heigl starred in the medical drama from 2005 until 2010, but gained a reputation as difficult to work with after making public complaints about her role in that and in the Judd Apatow film Knocked Up.

In 2008, she gave an interview describing Knocked Up as a little sexist and later said she hadnt entered herself for the Emmys for Greys Anatomy that year as I did not feel I was given the material this season to warrant a nomination.

Although Heigl later apologised to Apatow and Greys Anatomy creator Shonda Rhimes, clarifying her comments were about her own performances, she said the throwaway remarks had had a huge effect on her personally.

She told The Telegraph: It was this giant snowball effect. The more conscious of it I was, the more afraid I was, and the more I would say something stupid. It was this vicious cycle.

It was a public shaming. Even a little public bullying. And I took it really, really personally.

It had me confused about my own worth because I put all my value in other peoples opinions and suddenly those opinions changed.

Saying that she felt afraid about peoples opinions of her, she explained that it made her react in a negative way but that she felt her attitude had changed in recent years.

After the controversy in 2008, Heigl said she began to worry about saying things that would offend people in every interview.

The actress said that she now felt less insecure and wasnt so concerned about saying the wrong thing, adding if somebody chose to take it that way, thats on them.

Watch: James Marsden defends Katherine Heigl over difficult label

See the original post:
Katherine Heigl struggled with 'public shaming' after 'Grey's Anatomy' Emmy drama - Yahoo News

New York Times public editor: The anatomy of the Wolfe scandal – Columbia Journalism Review

Last Tuesday, the day before the inauguration of President Joe Biden, an editor at the New York Times found herself in a firestorm of online fury for a tweet she posted that afternoon: Biden landing at Joint Base Andrews now. I have chills.

Some, such as Glenn Greenwald, formerly of The Intercept, saw itand another tweet that followed, which described the Trump administration as childishas a sign that the media would not engage in adversarial coverage of the Biden administration. Many conservatives, like Fox News senior political analyst Brit Hume, saw it as a show of political bias.

By the time Biden was sworn in the next day, Lauren Wolfethe author of the tweethad been informed she was being fired.

Hume told me that while he believes journalists should be presented to the audience as neutral in their news coverage and thinks Wolfes tweet failed to meet that standard, it didnt seem to me to be a fireable offense.

But even after the saga received celebrity-scandal treatment on both sides of the Atlanticcomplete with a paparazzo dispatched to Wolfes Brooklyn neighborhood to snap a picture of her walking her dogmany of the basic facts of the story remain murky.

I spoke to Wolfe, who told me that she had been working as an editor on the Times Flexible Editing Desk, a unit in the newsroom that helps produce the live briefings on major stories, for about nine months. Her position was whats known at the Times as casual, meaning she was paid hourly, with no set schedule. Its intended as a temporary employment status, and Wolfe, who relied on the job as her sole source of income, had hopes of moving over to a full-time position.

Those hopes were dashed when she received a call from her bosss boss in the standards department. (The standards editor did not return my request for comment; Wolfe asked that his name not be included in this story.) I was told on the phone that the chills tweet was why I was fired, she says.

Wolfe says she tried to argue that her tweet was being misread. This was not even a political tweet. I had chills, meaning after the attempted overthrow of our government, the nightmare weve all been through, I had chills watching the democratic process work, she says. And I get where other people are like, I had chills for Biden, but that was not what I was saying. She says the standards editor told her, Im sorry, we cant have this. We cant have our name associated with such things. (Wolfe also says her direct boss, who did not return a call requesting comment, told her, For me, the chills tweet was fine, but the next onethe childish onewas not okay.)

For its part, a Times spokesperson told me, the paper is not going any further publicly than a statement it issued citing privacy concerns as the reason it would not go into its rationale for Wolfes dismissal: Theres a lot of inaccurate information circulating on Twitter. For privacy reasons we dont get into the details of personnel matters but we can say that we didnt end someones employment over a single tweet. Out of respect for the individuals involved we dont plan to comment further. (To clarify something that has been incorrectly reported, Ms. Wolfe was not a full-time employee, nor did she have a contract.)

This stance is standard practice among employers, to avoid giving terminated employees grounds for bringing claims against the companyand the New York Times Guild is currently negotiating on behalf of Wolfe with Times management after issuing a statement citing procedural concerns about her termination. But in this instance, the Times statementspecifically, its insinuation that there had been a pattern of behavioris Wolfes main complaint. I dont want to be hired back, she says. What I want is for them to retract this bullshit statement that makes me sound like some shitty employee that they used this as a final excuse for.

When I asked the Times for further details about any previous issues it had with Wolfes social media behavior, the paper declined, referring me to its statement. I asked Wolfe if there had been prior issues with her conduct on social media; the only incident she could think of was last fall, when she was warned by the standards editor that some of her tweets were bordering on inappropriate.

Paraphrasing, she says that the post at issue was something like Conservatives who wont wear masks are an example of extreme toxic masculinity. She was especially concerned because, in 2018, she had been one of the critics whom Trump blocked on Twitter, which led to a Knight First Amendment Institute lawsuit that went to the Supreme Court. But Wolfe was left with the impression that it was a routine review of the social media policy and, after deleting the tweet, thought the matter was resolved.

Wolfe, forty-five, says editing for the Times was a long-held ambition. I worship the Times, she tells me. I grew up in New York. To me it was the end-all-be-all thing. I mean, my first published story in life was at the Times. Getting a permanent job with the paper had been something of a quest for her.

Last spring, Wolfe leapt at the chance to start working on the Flex Desk and began the year optimistic that she was in line for a position on the new Live team, headed by national editor Marc Lacey, that was announced in early December.

Not being a full-time employee, she says, was also cited as one of the reasons she was fired. In her discussion with the standards department editor, Wolfe says, she was told, If you were full-time, we would have ways of disciplining you. And because youre not, we just have a much higher standard.

That just made me really fucking mad. Youre painting me as some weirdo freelancer. Its not true, she says. Im sorry. Im really emotional, because I loved my job and I know I did well. And Im just mortified theyd characterize me this way.

What is left is another example of how easy it is to derail a career with one tweet. The social media guidelines the Times demands its employees follow are vague, focused less on the content of a post and more on how it is read by others; the guidelines bar anything else that undercuts the Timess journalistic reputation or that appear[s] to take sides on issues. That means Times staffers do not have a clear way of knowing if theyre committing a fireable offense before they press post.

One of the terrible things about Twitter and one of the main reasons wed all probably be better off paying less attention to itthough, of course, I have just amplified it further with this columnis the way it can take a morsel of fact and, through a viral haze of likes and retweets, transform it into a grand and urgent saga.

And until the Times has clearer rules of the road for its newsroom, it would be understandable if more editors and reporters make the decision to simply stop tweeting.

TOP IMAGE: Adobe Stock

View post:
New York Times public editor: The anatomy of the Wolfe scandal - Columbia Journalism Review

Katherine Heigl Says Being Labeled as Difficult Amid Greys Anatomy Feud Caused Severe Anxiety – Us Weekly

Sorry, not sorry. Katherine Heigl admitted that backlash about her behind-the-scenes reputation took a major toll on her mental health after her Greys Anatomy exit.

I may have said a couple of things you didnt like, but then that escalated to shes ungrateful, then that escalated to shes difficult, and that escalated to shes unprofessional,' the 27 Dresses star recalled in a recent interview with The Washington Post, published on Thursday, January 28. What is your definition of difficult? Somebody with an opinion that you dont like? Now, Im 42, and that st pisses me off.

Heigl played Dr. Izzie Stevens on the long-running ABC drama for six seasons before ultimately leaving the show in 2010. Two years prior, she raised eyebrows when she withdrew herself for Emmys consideration because she didnt think the material she was given during season 4 was worthy of a nomination. Her comments quickly sparked rumors of tension between her and Greys creator Shonda Rhimes, who said at the time that she was surprised but not insulted by Heigls statement.

At the time, I was just quickly told to shut the fk up. The more I said I was sorry, the more they wanted it, Heigl continued. The more terrified and scared I was of doing something wrong, the more I came across like I had really done something horribly wrong.

After leaving Greys Anatomy, Heigl put more focus into her film career. However, the whispers about her behavior caused a shunning within the industry and she noticed that her films started to make not quite as much money. During her darkest moments, her husband, Josh Kelley, was very worried about the state of her mental health.

If she said [some of it] today, shed be a hero, Kelley, 40, told the outlet. I cant imagine what all of that pressure did to her over the years. It would be hard for anybody to process that, especially when its unjust and a lot of its negative.

Heigl married the singer-songwriter in 2007 and they adopted daughter Naleigh, now 12, two years later. In 2012, they adopted daughter Adalaide, now 8, and welcomed son Joshua in December 2016. One year before giving birth to her son, the Firefly Lane star experienced an extreme uptick in anxiety.

I asked my mom and my husband to find me somewhere to go that could help me because I felt like I would rather be dead, she recalled. I didnt realize how much anxiety I was living with until I got so bad that I had to really seek help. You can do a lot of inner soul work, but Im a big fan of Zoloft.

While Rhimes, 51, has previously made shady comments about Heigl in the years since their rumored feud began, the Knocked Up star has seemingly put the bad blood behind her. On Wednesday, January 27, she told E! News Daily Pop that she would never say never to making an appearance on the medical drama. Despite the ups and downs her career has faced, Heigl is comfortable making bold choices and advocating for herself on set.

Ive grown into accepting that ambition is not a dirty word, she told The Washington Post. And that it doesnt make me less of a feminine, loving, nurturing woman to be ambitious and have big dreams and big goals. Its easier to be happy because I have a little more gentleness for myself.

Continued here:
Katherine Heigl Says Being Labeled as Difficult Amid Greys Anatomy Feud Caused Severe Anxiety - Us Weekly

Katherine Heigl Hints at Possible Return to Greys Anatomy After Dramatic Exit: Never Say Never – Us Weekly

Water under the bridge? Katherine Heigl would be down to bring Izzie Stevens back to Greys Anatomy years after her dramatic 2010 exit.

I dont know, the Emmy winner, 42, told E! News Daily Pop during a virtual interview on Wednesday, January 27, when asked if she would ever return to the beloved ABC medical drama. But I would never say never.

Heigl starred on the Shonda Rhimes-created series from 2005 to 2010, departing from the show after its sixth season. Two years before she left, the New Years Eve actress sparked drama behind-the-scenes when she opted out of Emmy consideration because she didnt think the material she was given during season 4 warranted a nomination. At the time, Rhimes, 51, was surprised by Heigls comment but wasnt insulted.

I have a really wonderful working relationship with Katherine. Everybody knows Izzie is one of my favorite characters, she said, claiming that Katherine asked me to write her light story line for the second half of the season so that she could do her movie.

As rumors of tension between the showrunner and the 27 Dresses star continued to swirl, fans wondered how long Heigl would stay on the series. When her exit deal was finalized in the middle of season 6, Heigl said she wanted to focus on spending time with her family.

Reflecting on the circumstances of her departure, Heigl said she was really embarrassed when her comments went viral.

I went in to [see] Shonda and said, Im so sorry. That wasnt cool, and I should not have said that. And I shouldnt have said anything publicly, the Knocked Up star said on The Howard Stern Show in 2016. But at the time, I didnt think anyone would notice. I just quietly didnt submit and then it became a story, and I felt I was obligated to make my statement, and [I should have just said], Shut up, Katie.'

While Heigl has seemingly put her mistakes behind her, Rhimes threw shade at the Suits alum while discussing the culture on the Scandal set. There are no Heigls in this situation, she told The Hollywood Reporter in 2014. I dont put up with bullshit or nasty people. I dont have time for it.

Though she might not be walking the halls of Seattle Grace Mercy West Hospital anytime soon, Heigl is plotting a return to TV with the upcoming Netflix drama Firefly Lane, which hits the streaming platform in February. Working on the series which is based on Kristin Hannahs novel of the same name was like a breath of fresh air.

Every single one of us has probably had that experience where when you try to stand up for something or put your foot down about something, youre either hysterical or difficult or being a bitch, Heigl said on Wednesday. That didnt exist on this set. There was none of that and you felt really protected. It was phenomenal.

Read the original here:
Katherine Heigl Hints at Possible Return to Greys Anatomy After Dramatic Exit: Never Say Never - Us Weekly

Greys Anatomy Alum Katherine Heigl Finally Weighs In on Alex Leaving Jo: It Was an Ahole Move – Us Weekly

Dont hold back. Katherine Heigl finally weighed in on a shocking Greys Anatomy twist that saw Alex Karev (Justin Chambers) and her character, Izzie Stevens, reunited in season 16.

The Firefly Lane star, 42, told Entertainment Tonight she hasnt watched the episode, which aired in March 2020, but had some thoughts on her onscreen beaus behavior.

Wasnt he with someone? she said in the Wednesday, January 27 interview, referencing Alexs wife Jo (Camilla Luddington). Listen, isnt that an ahole move?

Alex and Izzies reunion on the show served as the end of Chambers story line. During the episode, viewers learned that the doctor left Seattle and reunited with his old love interest. Alex and Izzie were raising twin daughters on a horse farm in Kansas information he revealed to Jo and longtime friend Meredith (Ellen Pompeo) in a series of letters.

Viewers were taken aback by the plot point, but not entirely disappointed. Do I think this reunion makes sense? No. Do I care? Fk no. I got my Alex and Izzie endgame! one fan tweeted at the time. Another wrote, They killed all my other ships I will take this win idc idc idc Jo who? Alex and Izzie was my forever ship.

As for potentially returning to Greys Anatomy herself, Heigl isnt ready to write it off however unlikely it may be. Im super focused on this show and my passion for it, the Knocked Up star told ET. I would never say never but its not likely.

Heigl left Greys Anatomy in 2010 during season 6 of the show 10 seasons before Chambers surprised viewers by announcing his own exit. The actress left the show on a contentious note, after a public falling out with showrunner Shonda Rhimes. After being nominated for a Primetime Emmy in 2007 for her performance on the show, Heigl withdrew her name.

She said at the time, I did not feel that I was given the material this season to warrant an Emmy nomination and in an effort to maintain the integrity of the academy organization, I withdrew my name from contention.

Speaking with Howard Stern after the fact in 2016, the Washington, D.C., native revealed that she later apologized to Rhimes, 51, for her comments, noting that she was really embarrassed. The producer later named Heigl in a 2010 interview with The Hollywood Reporter about difficult actors to work with on set.

There are no Heigls in this situation, she said at the time, adding that she adopted a no aholes policy on set.

Excerpt from:
Greys Anatomy Alum Katherine Heigl Finally Weighs In on Alex Leaving Jo: It Was an Ahole Move - Us Weekly

Grey’s Anatomy, Scrubs and more coming to Disney+ in February – Digital Spy

Grey's Anatomy, Scrubs and Buffy the Vampire Slayer are among a number of shows heading to Disney+ this February as new entertainment brand Star prepares to launch.

Star will arrive on Disney+ in the UK and Ireland, as well as a number of other countries worldwide, on Tuesday, February 23 and will add more than 75 popular TV series, more than 270 movies, and four exclusive Star Originals to the Disney+ line-up at launch, with new titles to be added every month.

There are plenty of big-name TV shows coming to Star, including 24, Lost, Family Guy and The X-Files.

SIGN UP TO DISNEY+

Also on their way to Star are Atlanta, black-ish, Desperate Housewives, Glee, How I Met Your Mother, Modern Family, Prison Break and Scandal.

There will be a range of movies available too, including Oscar-winners The Favourite, The Grand Budapest Hotel and Three Billboards Outside Ebbing, Missouri. Classics will also be well-represented, from Pretty Woman and Moulin Rouge to Die Hard 2 and There's Something About Mary.

Superhero fans who have made their way through all of the Marvel content already on Disney+ will also be pleased to hear that Deadpool 2 is among the list of initial titles.

Related: Has Disney Plus stopped free trials in the UK in 2021?

As for the exclusive Star Originals, we'll initially be getting crime thriller series Big Sky, which comes from Big Little Lies creator David E Kelley, and Love, Simon spin-off series Love, Victor.

Also arriving at launch will be adult animated sitcom Solar Opposites from Rick & Morty co-creator Justin Roiland and writer Mike McMahan, and Marvel's horror series Helstrom, which focuses on Marvel Comics characters Daimon and Satana Helstrom.

Later in 2021 we can expect new series including Dopesick, starring Michael Keaton and Rosario Dawson, and The Dropout, featuring Kate McKinnon, as well as FX originals including the Jeff Bridges-starring The Old Man, plus new Kardashian-Jenner content.

This content is imported from Twitter. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

Disney+ is introducing new parental controls following Star's launch, including the ability to limit access to content on specific profiles based on content age ratings and the ability to add a PIN to lock profiles that have access to adult content.

Jan Koeppen, President of the Walt Disney Company EMEA, said: "Star will be an integral part of Disney+, making it bigger, bolder and even more exciting. The arrival of hundreds of TV series and movies including our exclusive Star Originals will make Disney+ the premier destination for high quality entertainment with something for everyone."

Star content on Disney+ will vary across different countries.

A Disney+ subscription in the UK currently costs 5.99 per month, or 59.99 annually. From February 23, when Star launches, the price will increase to 7.99 per month, or 79.90 annually.

Existing subscribers (those who subscribed prior to February 23) will continue to pay their current price for another six months, with their subscription price increasing to the new amount from August 22.

Sign Up for Disney+

Disney+Disney+

Maleficent: Mistress of Evil

Mary Poppins Returns (With Bonus Content)

Disney Princess - 11 Movie Keepsake Boxset [DVD] [2015]

The Jungle Book [DVD] [1967]

Peter Pan (1953) [Blu-ray] [Region Free]

Big Hero 6 [Blu-ray] [Region Free]

Bedknobs and Broomsticks [Blu-ray] [Region Free]

High School Musical 1-3 [DVD]

Digital Spy has launched its first-ever digital magazine with exclusive features, interviews, and videos. Check it out with a 1-month free trial, only on Apple News+.

Interested in Digital Spy's weekly newsletter? Sign up to get it sent straight to your inbox - and don't forget to join our Watch This Facebook Group for daily TV recommendations and discussions with other readers.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

More:
Grey's Anatomy, Scrubs and more coming to Disney+ in February - Digital Spy

Covid 19 coronavirus: New Zealand Grey’s Anatomy star Martin Henderson still in isolation after 19 days – New Zealand Herald

Martin Henderson and his girlfriend Aisha Mendez are in day 19 of quarantine. Photo / Martin Henderson, Instagram

New Zealand actor Martin Henderson and his partner Aisha Mendez are in day 19 of quarantine.

Yes, you read that correctly: day 19!

"Day 19 of isolation and we are both still alive," he wrote on Instagram.

"Thank goodness for the #pradacup such amazing entertainment."

So I guess there is a silver lining, as they have the Prada Cup to watch through the weekend.

Henderson and his partner returned to Aotearoa in early January.

It is believed they are isolating in an Auckland hotel.

This week the Pullman Hotel has been linked to three new cases within the community.

On Sunday it was revealed a Northland woman had contracted Covid-19 before leaving her 14-day spell at the Pullman on January 13.

A child and an adult - who were also staying at the Pullman hotel and left on January 15 - have also tested positive.

29 Jan, 2021 02:55 AMQuick Read

29 Jan, 2021 12:36 AMQuick Read

28 Jan, 2021 04:00 PMQuick Read

26 Jan, 2021 09:47 PMQuick Read

Tough new rules for exercise and smoking have been introduced at the Auckland managed isolation facility at the centre of the latest Covid community outbreak.

A returning Kiwi at the five-star Pullman hotel says new measures have been introduced overnight allowing returnees to get out of their rooms for limited times throughout the day.

But everyone wanting to escape their accommodation for some exercise or have a cigarette now must book a time slot.

She also mentioned there had been no communication from management about whether people who had finished their mandatory 14 days could yet leave.

Henderson and Mendez have been dating since last year, and have shared their romance openly on social media - posting cooking demos together, and behind-the-scenes snaps from their dates.

Henderson has also previously received congratulations on his relationship from two former co-stars: Jennifer Garner and Ellen Pompeo.

Garner, who played Henderson's wife in TV movie Miracles from Heaven, commented on one of his photos with Mendez, writing "I'm so happy for you," with love hearts.

Pompeo, who played his love interest on Grey's Anatomy, added in four red love hearts in support too.

In Henderson's latest TV role, in the Netflix romantic soap Virgin River, he plays Jack Sheridan, the love interest of Melinda Monroe, played by Alexandra Breckenridge.

Last month it was confirmed a third season is on the way.

Read more from the original source:
Covid 19 coronavirus: New Zealand Grey's Anatomy star Martin Henderson still in isolation after 19 days - New Zealand Herald

Anatomy of a Collapse: Reviewing what went wrong for the Toronto Raptors vs. the Indiana Pacers – RaptorsHQ

The Raptors failed to sweep their mini-series against the Indiana Pacers despite Kyle Lowrys return to action in the second game. Toronto was unable to match the defensive intensity that carried their team the previous night. They also did not have the same success behind the arc, giving them a much slimmer margin for error. And boy did they ever make some errors during Monday nights game.

Still, as we recapped here and here, the Raptors managed to stay within striking distance of the Pacers. It wasnt until the fourth quarter, really those final 10 minutes, when things really fell apart for the Raptors. This time there was no Pascal Siakam around to help (or use as a scapegoat), and Pacers coach Nate Bjorkgren, former assistant to coach Nick Nurse, knew how to exploit Torontos ongoing issues.

Before the collapse, the Raptors had a successful third quarter, outscoring the Pacers 37-28 behind an aggressive 1-2-2 zone defense that would shift into a 2-3 zone when the ball got lower than the above-the-break area. Meanwhile, Toronto capitalized on the Pacers defensive weakness in transition after every miss or live-ball turnover. At the end of the frame, it felt like the Raptors could pull out another shorthanded win in Indiana.

The final period saw the Raptors and the Pacers in a tight contest, with Toronto trailing 97-98. However, OG Anunoby was then taken out a minute into the quarter after taking Edward Sumners elbow to his mouth. Chris Boucher, who played most of the third, replaced Anunoby. The Raptors were down OGs presence on the offensive end, but the Stanley Johnson-Boucher-Yuta Watanabe frontcourt was still solid enough defensively.

Lets get into what happened over the next nine minutes. First, the Pacers starters Myles Turner and Malcolm Brogdon returned to the game, while DeAndre Bembry replaced Stanley Johnson for Toronto. Now, to break down the breakdown.

As seen above, Watanabe has inside position on Turner already. Bembry, coming off a rotation from the baseline, directs Watanabe to rotate to the perimeter to take on T.J. McConnell, whos not a threat even if he gets the ball there. Bembry now has to battle Turner down low, and ends up ceding the offensive rebound. As a result, Turner gets fouled for two more free throws.

Also part of the play: Boucher looked lost following the ball during the entire play, and the team had very little communication on defense. Fortunately, Turner made 1-of-2. Pacers now lead 103-102.

Here we see Norman Powell and Boucher set up for a pick-and-roll, but Norm refuses the screen to avoid the potential blitz. It was the right move, as the Pacers were overplaying the pick and Powell almost had a clean lane for a dunk. Unfortunately, Aaron Holiday was able to contest his shot, forcing a miss. Of course, Holiday was already roaming, as he did not have to respect Bembry as a threat behind the arc.

Lowry refused to attack the pick-and-roll set by Boucher, instead kicking out to Bembry, who was momentarily open in the perimeter. Bembry drove to the paint where three defenders were waiting for him. He found a wide-open Watanabe for a corner three (good!), but Yuta bricked it (bad!). Brogdon and Turner went on to run a well-executed pick-and-roll action the following play to open up Brogdon for a three-pointer. On defense, Powell didnt put up much of a fight through screens, and Boucher, with a bad read, got caught in between the action, unable to defend either play. Pacers lead 106-102.

The Raptors next possession had Lowry second-guessing what to do. He was able to shed McConnell via Bouchers pick in the backcourt, and he looked open for a perimeter shot. He took advantage of the opening, but it didnt work out. (I blame Lowrys toe infection, which had to still be bothering him.) Watanabe grabbed the rebound and attacked the basket, drawing a foul. The dead ball situation allowed Fred VanVleet to come in for Lowry.

The Raptors ran a SLOB play to get the ball to Powell, with him setting up on the weak side and Boucher waiting to give him an off-ball screen. Brogdon fights through the screen and snuffs the play, giving Watanabe two options: give the ball to Powell near half-court or give the ball to Bembry, who came up as another pass receiver.

He goes with the latter, which leads to Bembry and Watanabe executing a pick-and-roll. But the Pacers blitz pushes Bembry near the logo too with no concrete plan. To try and save the possession, Bembry tosses Powell a grenade with just four seconds to shoot, which means Norm has to put up a bad pull-up three-point attempt.

The Pacers came back running another pick-and-roll involving Turner, this time with the ball in McConnells hands. The blown coverage between Watanabe and Boucher has them both going after McConnell, which allows Turner to roll towards the basket. Hes fouled in the process, pushing the Pacers lead to 108-102. Fortunately, the Raptors came back with a nice set play, allowing Powell to quickly get up for the dunk, cutting the lead to 104-108.

The Raptors defense was late on closing out Brogdons drive to the basket, but Johnson stays with him the whole time. Boucher also comes over to offer additional rim protection though Johnson maybe doesnt need the help. It forces Brogdon to kick it out to McConnell in the weakside corner. VanVleet probably closes out too hard here or perhaps he was just tired.

McConnell is a career 33 percent behind the arc, and even if he made one earlier that game, he hasnt had made multiple three-pointers in a game since the last regular season game of 2018. So, of course, McConnell attacks the closeout and is able to get a layup on a slow-to-recover Boucher. Pacers push their lead to 110-104.

Bembry finally does something good the following play, forcing McConnells turnover, which spurs a Raptors attack in transition. Unfortunately, VanVleet tries to go into hero mode, attempting a difficult layup against multiple defenders. At the same time, Bembry and Powell are wide open on the perimeter for a kick-out. Bembry has the presence of mind to crash the boards and somehow tip in VanVleets miss, cutting the lead to 110-106.

The Raptors defended the Pacers next possession well for 20 seconds. Credit to Turner here, he hits tough hook shot over Bouchers outstretched arms. Maybe Bembry could have done more with the double team, seeing that Turner was not in a position to kick-out with just a few second left on the shot clock. Presumably, if that was Lowry or VanVleet, they would have dug in to force an even tougher shot, or perhaps a miss (or maybe even a steal but thats wishful thinking after-the-fact). The Pacers bump up their lead to 112-106.

Bembry attacks the basket hard trying to dunk on peoples heads, but he misses. Fortunately for Toronto and they needed all the help they could get by this point the ball bounces all the way back out to Boucher on the perimeter. He wisely makes a quick swing pass to VanVleet for a deep three-pointer. Now its 112-109 for Indy. Unfortunately, on the next play, the breaks of the game go against Toronto. The Raptors almost get a stop, with Boucher diving in for a steal but then getting ruled out of bounds. You can see Nurse calling a timeout in the background.

The Pacers go back to another Brogdon-Turner pick-and-roll, but this time the Raptors are playing closer man-to-man defense. Johnson switches to Brogdon, but cant quite stay in front of him on the drive. Johnsons slight bump results in another foul, instead of Lowrys anticipatory drawn charge call. Brogdons and-1 pushes the lead back up to 115-109, and maybe finally breaks Torontos will.

The Raptors come back with another tired legs play with not much working on offense. In the process, VanVleet fumbles the ball a bit trying to get in the paint, Powell has to create a drive-and-kick opportunity for VanVleet. And when the ball gets out to Fred... he air-balls the three-pointer.

Indiana gets yet another successful Brogdon-Turner pick-and-roll its this kind of offensive reliabilit
y the Raptors are missing when Siakam is out which nets them two more free throws. In their efforts, the Raptors are again late on their help defense and recovery and the game is now fully slipping away, with Toronto down 117-109. Anunoby returns after getting stitches in his mouth, but hes non-factor the rest of the way. Lowry, meanwhile, draws a foul on a dribble-hand-off play, stopping the clock and getting him two free throws. But by this time, its too little to late. After a foul on Lowry, and more free throws, its 118-111 with three minutes to go.

From there we see a contested floater from Lowry, more Turner free throws, and Norm getting blocked by Turner too. Not even Anunoby, whos been playing great could help, as his drive-and-kick to Boucher in the corner for three was a brick. Meanwhile, Brogdon, like Turner, just continued to have his way with Torontos defense. Unlike Sundays game, the Raptors could do little to stop him or Turner, and that was that on Monday night.

********

Ultimately, the Raptors failed to adjust to the whistle. But more importantly, they were unable to counter the Pacers adjustments in the fourth. After outfoxing Indy on Sunday, the Pacers game-planned Monday nights game really well. To start with, they made life difficult for Torontos primary ball handlers, picking them up fullcourt and funneling them into other Pacers defenders.

By doing this, the Pacers got Lowry and VanVleet to give up the ball by blitzing their screen actions. With Siakam to also help with the ball, Toronto was stuck and Nurse failed to come up with any other counter that worked, which allowed the Pacers to dictate who would run Torontos scrambled offense.

The Pacers also showed no respect to the Raptors ancillary players perimeter shooting, repeatedly leaving Watanabe, Johnson, Bembry, and even Lowry open on the perimeter. The Raptors didnt help matters by often failing to recognize when and where open teammates were from moment to moment. On the flip side, Toronto made terrible decisions by closing out on poor shooters like Aaron Holiday and T.J. McConnell, which often led to free throws, if not easy layups.

With all of these happening, Nurse was then dealt an even worse hand when Anunoby had to leave the game to get medical attention. Anunobys absence led to a massive drop off on the Raptors defensive effectiveness. Pressed into extended minutes, Bembrys presence was odd in this game he could force a turnover, sure, but other than that, he was not a factor defensively and was not in sync with his teammates defensive rotations. He was also treated with the same disrespect as Aron Baynes on the perimeter.

Not to put it all on him, but VanVleet outlined Torontos defensive issues in the fourth quarter they were not guarding and containing the ball, which allowed easy penetration from the Pacers playmakers. In all, Toronto just wasnt making those extra needed rotations, and part of that comes from making the right ones on time.

During his post-game interview, Nurse said the Raptors were not allowed to be physical given how the game was officiated. He has a case here, as the Pacers were allowed to bump, grab, and hold without getting those ticky-tack fouls the Raptors were whistled for throughout the game. However, the whistle was at least consistently unfavourable to the Raptors from the opening tip onward. Its easy to say this, but nevertheless: the team should have adjusted better to how the game was being called. In this, tired legs led to obvious grabbing, reach-ins, and late rotations that only made things worse.

Toronto just did not do themselves any favours in any facet of Mondays game down the stretch. Lowry did not look right, VanVleet looked gassed, there was no Siakam to draw attention, the defense got overly scrambled, and the offense was left entirely lifeless by the final buzzer. Could the Raptors have done something differently maybe playing more of Matt Thomas or giving Paul Watson a look? Its possible, but given how many things were working against them internally against the Pacers, it doesnt seem likely they alone would have turned it around for the Raptors.

See the article here:
Anatomy of a Collapse: Reviewing what went wrong for the Toronto Raptors vs. the Indiana Pacers - RaptorsHQ

President Review: Camilla Nielssons Extraordinary Documentary Traces the Alleged Theft of an Election – Variety

Democrats, Camilla Nielssons superb 2014 documentary about the tortuous construction of Zimbabwes 2013 constitution, was most riveting as a snapshot of a country still trying democracy on for size, wary of what it saw in the mirror. Studying the troubled coalition government that paired president Robert Mugabes long-ruling ZANU-PF party with the more liberal opposition of Morgan Tsvangirais Movement for Democratic Change (MDC) Alliance, Nielssons film posited any progress at all as fragile, easily undone by a volatile political system: Audiences might have left hoping for a more optimistic sequel, but hardly counting on one.

Even so, those who havent checked any headlines from Harare in the interim could hardly be prepared for the gut-punch of President, Nielssons galvanizing, epic-scale docuthriller tracking Zimbabwes corruption-riddled 2018 presidential election presented here as a brazen feat of hijacked democracy to make Donald Trump positively chartreuse with envy. As it premieres in Sundances world documentary competition, President may hit especially hard with audiences who have recently become all too familiar with talk of stolen elections as it depicts a scenario in which such accusations are backed by disturbing numeric discrepancies rather than wounded ego and bluster.

Not that Nielssons film panders to international viewers with hand-holding commentary or comparisons. Like Democrats, it is free of narration and direct talking heads, instead relying on the passive but insistent presence of Nielsson and DP Henrik Bohn Ipsens camera to navigate us through a thorny obstacle course of rallies, protests, procedural meetings and, in an urgent and heart-sinking final act, full-blown courtroom drama. Only a hefty 133-minute running time might give distributors some pause, but while President presents certain opportunities for judicious cutting, its never less than gripping, and will likely reach more eyeballs than its predecessor.

The film begins with a dramatic change of guard in both Zimbabwes main political parties, following the 2017 coup that saw veteran dictator Mugabe ousted by his own party, and replaced with his former vice Emmerson Mnangagwa. Less than three months later, Tsvangirais untimely death from cancer sees 40-year-old lawyer and activist Nelson Chamisa take over as MDC chief. With the next general election already set for that July, its a baptism of fire for the charismatic young Turk, who nonetheless brashly sets out his plan to break ZANU-PFs stranglehold on power: He wants to rule us with his walking stick? he says of Mnangagwa, to whoops of approval at an early electoral rally.

MDC brass believe they have the lions share of public support; they also know that wont necessarily translate to the official vote count, in a country that has previously been plagued by allegations of electoral fraud and rigging by the ruling party. Moreover, the opposition has a tetchy relationship with the supposedly impartial Zimbabwean Electoral Commission, responsible for carrying out the election and delivering the result. The filmmakers sit in on fraught conciliatory conferences between ZEC and party officials, which make for some of the films tensest, wittiest material as accusations of unfairness are volleyed back and forth: Rather like Frederick Wiseman, Nielsson has a knack for excavating savage drama from administrative process and politesse.

Away from airless meeting rooms and onto the sidewalk, a national mood of hostility is more pronounced. MDC supporters claim theyre being abused and intimidated by the authorities as aggressive an election-stealing tactic as any possible number-fudging though as one rally attendee remarks, not everyone can be suppressed into submission when theyre already failed by the system. Whether were beaten up or we die of hunger, were dead anyway, she shrugs.

These words rather haunt the film when a horrifying climax is reached and filmed, with astonishing in-the-moment access in the days immediately following the election. As ZEC inexplicably delays the announcement of the results, to the consternation of the MDC and a restless public, mass protests are met with military fire, leaving six dead and many others wounded; who ordered this rash action is a question that Mnangagwa coyly sidesteps. The more the process is protracted, meanwhile, the more heavily the beleaguered, death-threatened Chamisas earlier words weigh on him: If we miss this opportunity, we are doomed for life.

Working on a larger and (even) more logistically challenging canvas than in Democrats, Nielssons filmmaking maintains its poise and intelligence whether negotiating procedural banalities or frenzied panic in the streets. Along with Ipsen and editor Jeppe Bdskov, she devotes as much attention to conflicted faces and layered human exchanges as she does to dry facts, while sheer circumstance gifts the film with scenes as extravagantly absurd and unnerving as anything that could be scripted. A surprise press conference with the bruised, resentful Mugabe might not have Shakespearean levels of grandeur and gravitas, but is captivating precisely because the disgraced leader believes it does: Politics consistently creates its own tragedy and comedy, and this vital, devastating documentary knows when simply to stand in the crowd.

Read this article:
President Review: Camilla Nielssons Extraordinary Documentary Traces the Alleged Theft of an Election - Variety

‘Grey’s Anatomy’: Japril Was Terrible — Matthew and April Should Have Always Been the OTP – Showbiz Cheat Sheet

Greys Anatomy may be classified as a medical drama, but its full of steamy romances and heart-wrenching love stories. Meredith and McDreamy may have been the prom queen and king of the series, but another couple comes pretty close as far as fans are concerned.

Jackson and April were one of the fans favorite couples. When Matthew came into the mix and April found herself in a love triangle, fans everywhere chose sidesit was either Japril or Mapril, and nothing in between. Although April is no longer on the series, fans are still talking about Japril.

Some miss the couple and wish she had chosen to stay with Jackson, while others feel that she never should have left Matthew in the first place.

At first glance, April Kepner appeared to be the hospitals most naive, innocent resident when she arrived at Seattle Grace (now known as Grey Sloan Memorial). She was quiet, timid, and a bit awkward to boot. She had grown up on a farm, the youngest of three assertive sisters, and it definitely showed.

April showed everyone that they were wrong, however. She turned out to have a fiercely competitive spirit and unwavering drive. She took her job very seriously, and was willing to learn anything that could help her improve her skills. She also wasnt afraid to get her hands dirty and never backed down from a challenge.

The red-haired young resident was part of a merger between Seattle Grace and Mercy West. The beginning of her time on this newly merged team didnt go so well. A tragic hotel fire brought in a massive amount of patients, and amid all the chaos, April made a serious mistake on a patient.

She failed to check the patients airway, which ended up being filled with soot. She later went into cardiac arrest and died, and April was fired.

April was later rehired when Derek Shepherd became the new Chief of Surgery. Her confidence was very low after making a mistake that cost a patient her life, and she was reluctant to get back into surgery. Derek helped her see that she had incredible talent, and eventually she became comfortable enough to try again.

Jackson Avery may be undeniably gorgeous, but he also has a brilliant mind behind those clear green eyes. When Jackson joined the team at the hospital, he was already well-knownhis family was, anyway. His grandfather was the prestigious Harper Avery, one of the most famous surgeons in the entire country. In fact, he even had a coveted award named after him.

His familys wealth and notoriety paired with his good looks gave Jackson the label of a spoiled rich kid. His co-workers assumed he had been handed everything throughout his life (which he pretty much was), and that he had no grasp of hard work. In reality, Jackson actually pushed himself very hard because his family never did.

Jackson was a hero during a traumatic shooting at the hospital. The gunman, a widower who blamed Derek Shepherd for his wifes death, held Jackson and his fellow surgeon, Cristina, at gunpoint while they operated on Derek. In a stroke of genius, Jackson pretended that Derek had flatlined. The gunman was so relieved that hed achieved his revenge, he ended his rampage.

RELATED: Greys Anatomy: How Sarah Drew Really Feels About April and Jacksons Ending

Theres no denying that Jackson and April have had a tumultuous relationship. Their on-again, off-again romance has touched fans hearts, and most of them have a strong opinion on whether the two really belong together. Many people think April is better off married to Matthew, and has finally gotten the happy ending she deserved.

The turning point in Greys Anatomy came at April and Matthews beautiful wedding. Mid-ceremony, Jackson stood up and sat down several times, appearing to have some sort of mental crisis figuring out what he wanted to do. When he finally says that he loves her and wants her to be with him, April is shocked (as well as the guests). The two ran off together and she left Matthew behind.

Many fans on Reddit believe that April never should have left Matthew in the first place, since they ended up getting married years later anyway. I wish April had never left Matthew at the altar. They were a better couple than Japril. Others agreed, saying, I wish the same only because they put them back together in the end. At least then April would be with someone that has some pride.

Others disagree, saying that April needed that time to get Jackson out of her system. If she hadnt left him at the altar she probably wouldve cheated with Jackson anyway. They were in love. Even when she was engaged her and Matthew wouldve never worked the first time. Others feel that she made the right choice, because it wouldnt have been right for her to stay with Matthew when she really loved Jackson. You may think Matthew was a better match, but he wasnt the man she loved so it wouldve been unfair to him.

Whether you believe April should have ended up with Jackson or Matthew, the writers decided that Matthew was her best fit. Although, it is Greys Anatomy, where nothing is ever set in stone. Who knows what may happen in future seasons if April should decide to return

The rest is here:
'Grey's Anatomy': Japril Was Terrible -- Matthew and April Should Have Always Been the OTP - Showbiz Cheat Sheet

Three-man shortlists and three scouting tests anatomy of a Leicester City transfer – Leicestershire Live

Leicester City have just a few days remaining in the January transfer window to bring in the attacking midfielder they crave.

But how do they go about picking the player they will pursue? And how do they have such an enviable success rate in the transfer market? Here is a look at the process they go through.

Meeting of minds

The process starts with a meeting between manager Brendan Rodgers, head of recruitment Lee Congerton, who followed him down from Celtic, and City's director of football Jon Rudkin, and finishes with a list of three targets, ranked by preference, for Rudkin to chase up.

Rodgers explains: We will have a look at where the gaps are in the squad and where we want to improve. We'll then highlight the positions where we need to strengthen.

Then Lee will go away along with Jon and his team of people, they will then come up with the players that fit the profile of the market that we are in.

Video Unavailable

Click to playTap to play

Play now

Then, once they've done that, we'll sit down and look at the recommendations that come through. That's a whittled down number of players.

From there, there will be three options that we would be happy to get in. We hope we would get the number one option. That's the process.

And then once the player has been identified, Jon and Lee will go away and see if they can complete the deal for the club.

Three types of scouting

There is a mix of scouting involved in finding the right player. The recruitment team use statistics to pick out targets, and City have Mladen Sormaz in a recently-created head of analytics role to really drill down into the numbers, but any potential signing also has to pass the eye test, while calls are also put in to determine their personality.

Rodgers says: (Analytics) is a significant part of recruitment now but it has to be in balance.

We have Mladen here who does a lot of that work for us along with the other scouts. When we identify a player, he will specifically look at the statistics and that side of it.

Its always in balance because statistics will never tell you if a player has a heart, or what his technique is like. You can only see that when they play, and you get to know that with the people you speak with.

Its a useful tool, but so is someone having a good set of eyes and seeing the potential in a player.

Why are City so good?

A lot of Citys success has been on forward planning, and having a pipeline as Rodgers has described it.

When Harry Maguire left the club, Caglar Soyuncu was able to step up more seamlessly because he had been signed a year earlier and had been able to settle.

It was the same case for James Justin this season, the young full-back more confidently filling Ben Chilwells boots at left-back because he had 12 months experience under his belt.

Rodgers recently said that City have a pipeline for every player in the squad, with lists that are constantly being updated with the latest names.

Brendan Rodgers has kept his powder dry this January, but there is time for that to change before transfer deadline day on Monday, with window closing at 11pm.

You can keep across all the latest news and rumours around ins and out for the Foxes in our daily Leicester City bulletin. We'll be bringing you the latest breaking news, transfer features and comment pieces, as well as the key talking points for fans.

It's easy and only takes seconds.

Simply type your email address into the box at the top of this article and hit sign up.

And that's it, you're all set. You can also sign up here.

If you decide later that you no longer wish to receive the emails, simply follow the unsubscribe link in one of the newsletters - but we don't think you'll want to.

We also have a Leicestershire Live app you can download below.

Download the Android app on Google Play

Download the App from the Apple Store

On how City have been so successful, Rodgers says: Its understanding the market youre in. We know the types of players we want to bring in. Well never be spending 60m to 80m on a player. We have a profile of a player that we like and that we want and that fits into the model of our game and we will be competitive in trying to get that player in.

When theyve come in, theyve been great. Lee and his team have been fantastic, getting in players like Wesley, and James Justin, hes been outstanding. If you look at the other players, Dennis Praet has come in and been very good, Timothy Castagne, Ayo Perez has been very efficient.

Its a huge credit to them, they do a great job, and we get amazing support from the owners.

See the rest here:
Three-man shortlists and three scouting tests anatomy of a Leicester City transfer - Leicestershire Live

Inherited blindness has a new cure, thanks to CRISPR – Genetic Literacy Project

In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness.

Researchers at U.S.-based Editas Medicine and Ireland-based Allergan have administeredCRISPR for the first time to a person with a genetic disease. This landmark treatment uses the CRISPR approach to a specific mutation in a gene linked to childhood blindness. The mutation affects the functioning of the light-sensing compartment of the eye, called the retina, and leads to loss of the light-sensing cells.

According to the World Health Organization,at least 2.2 billion peoplein the world have some form of visual impairment. In the United States, approximately200,000 people suffer from inherited forms of retinal diseasefor which there is no cure. But things have started to change for good. We can now see light at the end of the tunnel.

I am an ophthalmology and visual sciences researcher, and am particularly interested in these advances becausemy laboratory is focusingon designing new and improved gene therapy approaches to treat inherited forms of blindness.

Gene therapy involves inserting the correct copy of a gene into cells that have a mistake in the genetic sequence of that gene, recovering the normal function of the protein in the cell. The eye is an ideal organ for testing new therapeutic approaches, including CRISPR. That is because the eye is the most exposed part of our brain and thus is easily accessible.

The second reason is that retinal tissue in the eye is shielded from the bodys defense mechanism, which would otherwise consider the injected material used in gene therapy as foreign and mount a defensive attack response. Such a response would destroy the benefits associated with the treatment.

In recent years, breakthrough gene therapy studies paved the way to thefirst ever Food and Drug Administration-approved gene therapy drug, Luxturna TM, for a devastating childhood blindness disease,Leber congenital amaurosisType 2.

This form of Leber congenital amaurosis is caused by mutations in a gene that codes for a protein called RPE65. The protein participates in chemical reactions that are needed to detect light. The mutations lessen or eliminate the function of RPE65, which leads to our inability to detect light blindness.

The treatment method developed simultaneously by groups at University of Pennsylvania and at University College London and Moorefields Eye Hospital involvedinserting a healthy copy of the mutated genedirectly into the space between the retina and the retinal pigmented epithelium, the tissue located behind the retina where the chemical reactions takes place. This gene helped the retinal pigmented epithelium cell produce the missing protein that is dysfunctional in patients.

Although the treated eyes showed vision improvement, as measured by the patients ability to navigate an obstacle course at differing light levels,it is not a permanent fix. This is due to the lack of technologies that can fix the mutated genetic code in the DNA of the cells of the patient.

Lately, scientists have been developing a powerful new tool that is shifting biology and genetic engineering into the next phase. This breakthroughgeneeditingtechnology, which is called CRISPR, enables researchers to directly edit the genetic code of cells in the eye and correct the mutation causing the disease.

Children suffering from the disease Leber congenital amaurosis Type 10 endure progressive vision loss beginning as early as one year old. This specific form of Leber congenital amaurosis is caused by a change to the DNA that affects the ability of the gene called CEP290 to make the complete protein. The loss of the CEP290 protein affects the survival and function of our light-sensing cells, called photoreceptors.

One treatment strategy is to deliver the full form of the CEP290 gene using a virus as the delivery vehicle. But the CEP290 gene is too big to be cargo for viruses. So another approach was needed. One strategy was to fix the mutation by using CRISPR.

The scientists at Editas Medicine first showed safety and proof of the concept of the CRISPR strategy in cells extracted from patient skin biopsy and in nonhuman primate animals.

These studies led to the formulation of thefirst ever in human CRISPR gene therapeutic clinical trial. This Phase 1 and Phase 2 trial will eventually assess the safety and efficacy of the CRISPR therapy in 18 Leber congenital amaurosis Type 10 patients. The patients receive a dose of the therapy while under anesthesia when the retina surgeon uses a scope, needle and syringe to inject the CRISPR enzyme and nucleic acids into the back of the eye near the photoreceptors.

To make sure that the experiment is working and safe for the patients, the clinical trial has recruited people with late-stage disease and no hope of recovering their vision. The doctors are also injecting the CRISPR editing tools into only one eye.

An ongoing project in my laboratory focuses on designing a gene therapy approach for the same gene CEP290. Contrary to the CRISPR approach, which can target only a specific mutation at one time, my team is developing an approach that would work for all CEP290 mutations in Leber congenital amaurosis Type 10.

This approach involves usingshorter yet functional forms of the CEP290 proteinthat can be delivered to the photoreceptors using the viruses approved for clinical use.

Gene therapy that involves CRISPR promises a permanent fix and a significantly reduced recovery period. A downside of the CRISPR approach is the possibility of an off-target effect in which another region of the cells DNA is edited, which could cause undesirable side effects, such as cancer. However, new and improved strategies have made such likelihood very low.

Although the CRISPR study is for a specific mutation in CEP290, I believe the use of CRISPR technology in the body to be exciting and a giant leap. I know this treatment is in an early phase, but it shows clear promise. In my mind, as well as the minds of many other scientists, CRISPR-mediated therapeutic innovation absolutely holds immense promise.

In another study just reported in the journal Science, German and Swiss scientists have developeda revolutionary technology, which enables mice and human retinas to detect infrared radiation. This ability could be useful for patients suffering from loss of photoreceptors and sight.

The researchers demonstrated this approach, inspired by the ability of snakes and bats to see heat, by endowing mice and postmortem human retinas with a protein that becomes active in response to heat. Infrared light is light emitted by warm objects that is beyond the visible spectrum.

The heat warms a specially engineered gold particle that the researchers introduced into the retina. This particle binds to the protein and helps it convert the heat signal into electrical signals that are then sent to the brain.

In the future, more research is needed to tweak the ability of the infrared sensitive proteins to different wave lengths of light that will also enhance the remaining vision.

This approach is still being tested in animals and in retinal tissue in the lab. But all approaches suggest that it might be possible to either restore, enhance or provide patients with forms of vision used by other species.

Hemant Khanna is an Associate Professor of Ophthalmology at the University of Massachusetts Medical School. His lab investigates molecular and cell biological bases of severe photoreceptor degenerative disorders, such as Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA). Find Hemant on Twitter @khannacilialab

A version of this article was originally published at the Conversation and has been republished here with permission. The Conversation can be found on Twitter @ConversationUS

See more here:
Inherited blindness has a new cure, thanks to CRISPR - Genetic Literacy Project

Gene editing: beyond the hype – – pharmaphorum – pharmaphorum

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space.

Cutting edge is, for once, a truly apt description when it comes to gene editing both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome.

This has, of course, garnered immense excitement Doctors Emmanuelle Charpentier and Jennifer Doudna were named winners of the Nobel Prize for chemistry in recognition of their discovery of CRISPR/Cas9 gene editing technology.

Since that discovery, a flurry of gene-editing focused biopharma companies have launched including Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences and Mammoth Biosciences and the first drug therapies based on the technology are now in human testing for diseases like cancer.

California-based Sangamo Therapeutics is one such company that believes in the powerful potential of in vivo genome editing and regulation, together known as genome engineering, and has built up a sizable preclinical pipeline of genome regulation treatments for diseases such as Huntingtons disease and Amyotrophic lateral sclerosis (ALS).

But when I spoke to CEO Sandy Macrae during the JP Morgan Health Care Conference 2021, he stressed that companies cannot be successful in the area unless they are wise about the hype, and understand that focusing purely on in vivo editing is unlikely to be financially viable for some time.

Zinc fingers

Macrae had previously worked at GSK and Takeda before he was recruited by Sangamo.

Maybe in 50 years time well be using gene editing to lower cholesterol, but it wont replace statins in anyone but those with life threatening mutations for a long time

They wanted someone who had lots of experience in drug development, was a molecular biologist, and was stubborn enough to take on CRISPR! he jokes.

Since Macrae joined the company just four years ago, Sangamo has more than tripled its staff and raised $1.6 billion in funding. It has also built its own manufacturing site and launched partnerships with six big pharma companies.

This growth reflects the continued and increasing interest in gene therapy and with stock prices rising for editing companies across the board, Macrae says there has never been a more interesting time to be in genomic medicine.

When I started in 2016 it was still a very academic field without much industrial interest. Then over the next two or three years, gene therapy was accepted as something that companies got involved in, and several biotechs have been bought up by big pharma.

And Macrae notes that we still dont even know the full potential for the field.

At the moment its mostly being applied to ultra-rare diseases. That can be incredibly effective, but it doesnt allow for a sustainable business model. Thats why companies like ours have decided to move into larger unmet medical needs such as transplant, multiple sclerosis, or inflammatory bowel disease.

The companys primary technology is its zinc finger (ZF) platform. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, which are proteins that can be used to edit genomes by knocking select genes in or out to specifically modify DNA sequences.

ZFPs can also be engineered to make ZFP transcription-factors, or ZFP-TFs, which are proteins that can be used to regulate genomes by selectively increasing or decreasing gene expression.

Zinc fingers are the most common control gene in the body, Macrae explains. We can place them near the promoter of a gene and repress or upregulate it.

The exact mechanism depends on the disease in question. For example, the company is working on repressing promoter genes in tauopathies in collaboration with Biogen, but its partnership with Novartis is focused on upregulating genes related to autism, both leveraging the ZFP-TF platform.

The genomic medicine journey

Genome editing and regulation are still in their early stages, though, and Macrae says the fields evolution is likely to come in waves.

First of all it will be used for ultra-rare monogenic disease. Then itll be used for common monogenic disease, then polygenic disease or diseases where theres a genetic component. And ultimately we will be able to add genetic influences to diseases that dont have a genetic cause. Hypertension is one example there are probably 20-30 genes that control your hypertension, and perhaps one day well be able to identify which ones we can turn up or down.

Thats some way off, but it could be a whole new way of treating people.

That said, Macrae notes that the industry needs to be cautious about this hype.

We have to be thoughtful and prudent, because the worst thing that could happen is that gene editing is used in the wrong kind of patient, where theres a risk without a benefit. That would just slow the whole field down.

This is still a new area of medicine, and every company is realising that we dont always know as much about some of these rare diseases as we thought we did. Weve never had treatments for these conditions before, and now that we do we often find that we need to know a lot more about the physiology and the pathology of the disease than we imagined.

Many companies in this area tell wonderful stories about preclinical potential, but once youre in a clinical trial it doesnt matter how clever your science is what matters is whether the patient gets better, and because of that you really need to understand the potential risk.

Gene editing, he says, still has to go through a long journey to truly reach this potential.

That involves collecting as much safety data and uncovering as much about the benefit-risk profile as we can, Macrae says. The benefit-risk for a child thats going to die without treatment is unquestioned. The benefit for lowering your cholesterol, when there are other tools you can use, is more uncertain. We shouldnt go there until we have enough data to be sure that its safe.

Maybe in 50 years time well be using gene editing for things like that but while many patients might benefit from gene editing for lowering cholesterol, its not going to replace statins for anyone but those with life threatening mutations for a long time.

On top of this, there are the well-documented manufacturing challenges that come with such a new field.

I think weve all learnt that we need to spend more time earlier on in developing the industrial processes, Macrae says.

The call I get most often from headhunters is, Do you know anyone that can do manufacturing in cell therapy? The field has grown so rapidly that there are very few people with experience in it. There is also a shortage of manufacturing sites.

This is part of the reason Sangamo has built its own manufacturing site in California and is building a European site in France.

Owning your own fate in manufacturing is really important, says Macrae. The process of gene editing needs lots of care and attention, and were at an early stage of the science where we dont know all the answers. Thats why its so important to have your own people in-house who know how to do it well.

Pragmatic genomics

As such, while Sangamo strongly believes in the potential of in vivo genome editing and regulation, Macrae says that early on the company made a pragmatic decision that it shouldnt depend on the field becoming financially viable anytime soon, and required a near-term strategy that would bring in revenue and benefit patients.

That is why the company is also working on gene therapy and ex vivo gene-edited cell therapy.

If youre working in gene editing, you can also work in gene therapy, because you already know a lot about delivery, vectors, molecular biology etc.
, Macrae explains. So it seemed like a sensible decision for us to work on that while gene editing is still an evolving field.

The companys gene therapy pipeline now includes treatments for PKU, Fabry disease and hemophilia A (in partnership with Pfizer).

The next easiest area for the company to take on with its existing capabilities was ex vivo gene-edited cell therapy.

In this area, Macrae says he is most excited about the companys CAR-Treg platform, from its acquisition of French company TxCell.

Tregs travel to the site of the inflammation and release mediators to calm it. We can put our localising CAR onto the Treg, which takes it specifically where we want it to go. For example, for multiple sclerosis you can use a CAR that takes the Treg to the myelin sheath.

You dont need to know the cause of the disease, you just need to know where the disease is.

Sangamo still anticipates, though, a time when in vivo genome editing and regulation is just as key to the business as these other two pillars and in fact Macrae anticipates that over time, Sangamo will shift its development focus to genome engineering as the field and science mature.

Gene therapy can ultimately only take you into the liver, he explains. There are 7,000 liver diseases, and only 10-20 of them that are big enough to run large clinical trials. Most of them are rare mutations.

Everyone is going to the liver and doing the same disease, and what was already a small population gets sliced and diced between several companies. We therefore dont see it as a long-term sustainable opportunity.

We have the advantage of also being able to edit cells in vivo, and eventually we will be able to do fundamental once-and-done editing in other tissues. Its just a matter of getting the field there.

About the interviewee

Sandy Macrae has served as Sangamos president and chief executive officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry most recently serving as the global medical officer of Takeda Pharmaceuticals. From 2001 to 2012, Dr Macrae held roles of increasing responsibility at GlaxoSmithKline, including senior vice president, Emerging Markets Research and Development (R&D).

About the author

George Underwood is pharmaphorums Deep Dive magazine editor. He has been reporting on the pharma and healthcare industries for seven years and has worked at a number of leading publications in the UK.

Original post:
Gene editing: beyond the hype - - pharmaphorum - pharmaphorum

Exacis Biotherapeutics Announces Key Addition To Its Executive Leadership Team With Dirk Huebner MD Joining As Chief Medical Officer – PRNewswire

CAMBRIDGE, Mass., Jan. 29, 2021 /PRNewswire/ --Exacis Biotherapeutics, Inc., a development-stageimmuno-oncology company working to harness the immune system to cure cancer,today announcedthe addition of Dirk Huebner,MD,as its Chief Medical Officer. Exacis launched in 2020 to develop next generation mRNA-based cellular therapeutics to treat liquid and solid tumors.

Exacis CEO Gregory Fiore MD said, "Dirk is a wonderful addition and a great fit for our management team. His extensive experience in oncology drug development, including antibody related therapies will be instrumental as we build our pipeline to include high performance stealth edited NK and T cells, with and without CARs (ExaNK, ExaCAR-NK and ExaCAR-T). We look forward to Dirk's insights and medical leadership as we build the company and advance our portfolio."

Dr. Huebner joins Exacis from Mersana Therapeutics where he wasthe Chief Medical Officer,oversaw their clinical developmentand helped build thecompany'sclinical infrastructure. Dr Huebnerhas worked in oncology and immuno-oncology drug development and academiafor more than 25 yearsand brings a deep understanding of the needs in the oncology space as well as the ability to successfully deliverproducts to meet those needs.

Commenting on the new role, Dr. Huebner said, "I am thrilled to join the Exacis team and work with best-in-class technology to create innovative, next-generation engineered NK and T cell therapies that have the potential to improve outcomes and treatment experiences for patients with challenging hematologic and solid tumor malignancies."

About Exacis Biotherapeutics

Exacis is a development stageimmuno-oncologycompany focused on harnessing the human immune system to cure cancer. Exacis uses its proprietary mRNA-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors.Exacis was founded in 2020 with an exclusive license to a broad suite of patents covering the use ofmRNA-based cell reprogramming and gene editing technologiesfor oncology.

ExaNK, ExaCAR-NK and ExaCAR-T utilize mRNA cell reprogramming and mRNA gene editing technologies developed and owned by Factor Bioscience. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all global development and commercial rights for these investigational candidates.

About T and Natural Killer (NK) Cell Therapies

T and NK cells are types of human immune cells that are ableto recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.

SOURCE Exacis Biotherapeutics, Inc.

View post:
Exacis Biotherapeutics Announces Key Addition To Its Executive Leadership Team With Dirk Huebner MD Joining As Chief Medical Officer - PRNewswire

CRISPR and CAS Gene Market to Score Past US$ 7603.8 Million Valuation by 2027: CMI KSU | The Sentinel Newspaper – KSU | The Sentinel Newspaper

Global CRISPR and CAS GeneMarket, By Product Type (Vector-based Cas and DNA-free Cas), By Application (Genome Engineering, Disease models, Functional Genomics, Knockdown/activation, and Other Applications), By End User (Biotechnology and Pharmaceutical Companies,Academic Government Research Institutes, and Contract Research Organizations), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1,388.1 million in 2017, and is projected to exhibit a CAGR of 20.8% over the forecast period (2018 2026).

Manufacturers in the CRISPR and CAS gene are collaborating with many companies for sponsoring clinical trials. Editas Medicine has licensed CRISPR and other gene editing patent rights from the Broad Institute, the Massachusetts Institute of Technology (MIT), Harvard University, and others. In March 2017, Editas reportedly entered into an agreement with Irish pharmaceutical company Allergan under, which Editas was to receive a US$ 90 million up-front payment for an option to license up to five preclinical programs targeting eye disease. Moreover, various organizations are also focusing on new clinical trials for the CRISPR and CAS gene for cancer treatment. In 2018, CRISPR Therapeutics and Vertex launched the first in-human clinical trial of CRISPR genome editing technology sponsored by U.S. companies. The trial is testing an experimental therapy for the blood disorder -thalassemia in Regensburg, Germany.

Request for a Sample Report of CRISPR and CAS Gene Market:https://www.coherentmarketinsights.com/insight/request-sample/2598

Increasing research and studies regarding the CRISPR and CAS gene technology is majorly driving the growth of CRISPR and CAS gene market. In 2017, Editas partnered with Juno Therapeutics for cancer-related research using CRISPR. Under the terms of the agreement, Juno had to pay Editas an initial payment of US$ 25 million, in which up to US$ 22 million will be used in research support for three programs over five years. Editas has also engaged in a three-year research and development (R&D) collaboration deal with San Raffaele Telethon Institute for Gene Therapy to research and develop next generation stem cell and T-cell therapies for the treatment of rare diseases.

Get Discount For Buyers UPTO 30% OFF On Any Research ReportApply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Buy This Complete A Business Report @:https://www.coherentmarketinsights.com/insight/buy-now/2598

Detailed Segmentation:

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact Us

Mr. Shah1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027sales@coherentmarketinsights.com

View post:
CRISPR and CAS Gene Market to Score Past US$ 7603.8 Million Valuation by 2027: CMI KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper